EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY-NC 4.0

Exploiting blood-based biomarkers to align preclinical models with human traumatic brain injury

Ilaria Lisi, Federico Moro iD, Edoardo Mazzone, Niklas Marklund, Francesca Pischiutta iD, Firas Kobeissy iD, Xiang Mao iD, Frances Corrigan, Adel Helmy, Fatima Nasrallah iD, Valentina Di Pietro, Laura B Ngwenya und 10 weitere

Brain · 2025

DOI: 10.1093/brain/awae350 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Brain, 2025. Verfasst von Ilaria Lisi und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Acute Brain and Cardiovascular Injury, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan 20156, Italy. Hauptthemen laut MEDLINE: Brain Injuries, Traumatic, Biomarkers, Disease Models, Animal. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 161 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rodent models are important research tools for studying the pathophysiology of traumatic brain injury (TBI) and developing new therapeutic interventions for this devastating neurological disorder. However, the failure rate for the translation of drugs from animal testing to human treatments for TBI is 100%. While there are several potential explanations for this, previous clinical trials have relied on extrapolation from preclinical studies for critical design considerations, including drug dose optimization, post-injury drug treatment initiation and duration. Incorporating clinically relevant biomarkers in preclinical studies may provide an opportunity to calibrate preclinical models to identical (or similar) measurements in humans, link to human TBI biomechanics and pathophysiology, and guide therapeutic decisions. To support this translational goal, we conducted a systematic literature review of preclinical TBI studies in rodents measuring blood levels of clinically used GFAP, UCH-L1, NfL, total-Tau (t-Tau) or phosphorylated-Tau (p-Tau) published in PubMed/EMBASE up to 10 April 2024. Although many factors influence clinical TBI outcomes, many of those cannot routinely be assessed in rodent studies (e.g. intracranial pressure monitoring). Thus we focused on blood biomarkers’ temporal trajectories and discuss our findings in the context of the latest clinical TBI biomarker data. Of 805 original preclinical studies, 74 met the inclusion criteria, with a median quality score of 5 (25th–75th percentiles: 4–7) on the CAMARADES checklist. GFAP was measured in 43 studies, UCH-L1 in 21, NfL in 20, t-Tau in 19 and p-Tau in seven. Data from rodent models indicate that all biomarkers exhibited injury severity-dependent elevations with distinct temporal profiles. GFAP and UCH-L1 peaked within the first day after TBI (30- and 4-fold increases, respectively, in moderate-to-severe TBI versus sham), with the highest levels observed in the contusion TBI model. NfL peaked within days (18-fold increase) and remained elevated up to 6 months post-injury. GFAP and NfL show a pharmacodynamic response in 64.7% and 60%, respectively, of studies evaluating neuroprotective therapies in preclinical models. However, GFAP's rapid decline post-injury may limit its utility for understanding the response to new therapeutics beyond the hyperacute phase after experimental TBI. Furthermore, as in humans, subacute NfL levels inform on chronic white matter loss after TBI. t-Tau and p-Tau levels increased over weeks after TBI (up to 6- and 16-fold, respectively); however, their relationship with underlying neurodegeneration has yet to be addressed. Further investigation into biomarker levels in the subacute and chronic phases after TBI will be needed to fully understand the pathomechanisms underpinning blood biomarkers’ trajectories and select the most suitable experimental model to optimally relate preclinical mechanistic studies to clinical observations in humans. This new approach could accelerate the translation of neuroprotective treatments from laboratory experiments to real-world clinical practices.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain Injuries, TraumaticBiomarkersDisease Models, AnimalAnimalsHumansGlial Fibrillary Acidic ProteinUbiquitin ThiolesteraseRatstau Proteins

Stichwörter der Autor:innen

blood biomarkersdisease trajectoriesmodel calibrationtranslational researchtraumatic brain injury

Substanzen

BiomarkersGlial Fibrillary Acidic ProteinUbiquitin Thiolesterasetau Proteins

Autor:innen und Institutionen

  • Department of Acute Brain and Cardiovascular Injury, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan 20156, Italy.
  • Department of Clinical Sciences Lund, Neurosurgery, Lund University and Skåne University Hospital, Lund 222 42, Sweden.
  • Department of Neurobiology, Center for Neurotrauma, Multiomics & Biomarkers, Morehouse School of Medicine, Atlanta, GA 30310, USA.
  • Department of Neurosurgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230022, China.
  • School of Biomedicine, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide 5005, Australia.
  • Division of Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0QQ, UK.

ORCID-Profile: Federico Moro, Francesca Pischiutta, Firas Kobeissy, Xiang Mao, Fatima Nasrallah, David K Menon, David J Loane, Elisa R Zanier

Förderung

  • NINDS NIH HHS

Zitieren

APA

Lisi, I., Moro, F., Mazzone, E., Marklund, N., Pischiutta, F., Kobeissy, F., Mao, X., Corrigan, F., Helmy, A., Nasrallah, F., Pietro, V. D., Ngwenya, L. B., Portela, L. V., Semple, B. D., Schneider, A. L. C., Arrastia, R. D., Menon, D. K., Smith, D. H., Wellington, C., …, & Zanier, E. R. (2025). Exploiting blood-based biomarkers to align preclinical models with human traumatic brain injury. Brain. https://doi.org/10.1093/brain/awae350

Vancouver

Lisi I, Moro F, Mazzone E, Marklund N, Pischiutta F, Kobeissy F, et al. Exploiting blood-based biomarkers to align preclinical models with human traumatic brain injury. Brain. 2025. doi:10.1093/brain/awae350

BibTeX
@article{Lisi2025,
  author = {Lisi, Ilaria and Moro, Federico and Mazzone, Edoardo and Marklund, Niklas and Pischiutta, Francesca and Kobeissy, Firas and Mao, Xiang and Corrigan, Frances and Helmy, Adel and Nasrallah, Fatima and Pietro, Valentina Di and Ngwenya, Laura B and Portela, Luis V and Semple, Bridgette D and Schneider, Andrea L C and Arrastia, Ramon Diaz and Menon, David K and Smith, Douglas H and Wellington, Cheryl and Loane, David J and Wang, Kevin K W and Zanier, Elisa R},
  title = {Exploiting blood-based biomarkers to align preclinical models with human traumatic brain injury},
  journal = {Brain},
  year = {2025},
  doi = {10.1093/brain/awae350}
}
Kostenlos starten →